December 12, 2024 16:32 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Amid Atul Subhash row, SC says mere harassment is not enough to prove abetment to suicide | India's D Gukesh becomes youngest ever world champion in chess | Devendra Fadnavis meets PM Modi amid suspense over Maharashtra portfolio allocation | Congress wants to deviate the issue of Sonia Gandhi-George Soros link: JP Nadda | Bengaluru techie suicide: Atul Subhash's family demanded Rs. 10 lakh as dowry leading to my father's death, claims estranged wife | Syria rebels torch tomb of ousted president Bashar al-Assad's father | Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | Bengaluru techie's suicide: Atul Subhash's wife and her family booked
COVAXIN

Covaxin's efficacy result will help getting WHO's approval : Govt expert body chief

| @indiablooms | Jul 04, 2021, at 02:04 am

New Delhi/IBNS: India-made Covaxin's recently published result on efficacy will help the vaccine in getting World Health Organisation’s (WHO) emergency approval, the chairperson of National Technical Advisory Group on Immunisation in India (NTAGI), Dr NK Arora said on Saturday.

“This will help to get the vaccine WHO emergency use listing,” Arora told news agency ANI.

The NTAGI chairman also said the approval from the UN health body will bring visibility to India since Covaxin is indigenously developed.

Hyderabad-based biotechnology company Bharat Biotech has claimed its anti-COVID-19 vaccine, Covaxin, is 77.8% effective against the deadly virus.

Bharat Biotech made the claim in the phase three clinical trial data of the vaccine.

The company has further claimed Covaxin is 93.4% effective against severe symptomatic COVID-19 cases, 63.6% against asymptomatic COVID-19 cases and 65.2% against the Delta variant.

“Efficacy analysis demonstrates Covaxin to be 77.8% effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic Covid-19,” the manufacturer said in a paper published in open access journal medRxiv.

"We are working closely with the World Health Organisation for inclusion of Covaxin in its Emergency Use Listing. Approval from WHO is not expected to be a long drawn process as the cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past," Ella tweeted.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.